Condition: Endometrial Cancer Stage I · Endometrial Cancer Stage II · Sponsor: Women's Hospital School Of Medicine Zhejiang University
This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.
This description comes directly from the study's public registry record.
Xinyu Wang, MD · +86-571-87061501 · wangxinyu@zju.edu.cn
Yang Li, PhD · +86-571-87061501 · li_yang@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Tongji Hospital, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| Women's Hospital School of Medicine Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| Peking University Peoples Hospital | Beijing, China | Not Yet Recruiting |
| Xiangya Hospital of Central South University | Changsha, China | Recruiting |
| Sun Yat-Sen University Cancer Hospital | Guangzhou, China | Not Yet Recruiting |
| Ningbo First Hospital | Ningbo, China | Recruiting |
| Ningbo Women and Children's Hospital | Ningbo, China | Recruiting |
| Obstetrics & Gynecology Hospital of Fudan University | Shanghai, China | Not Yet Recruiting |
| Shanghai First Maternity and Infant Hospital | Shanghai, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05179447